{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:11:23Z","timestamp":1794028283030,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017559","name":"Recordati Rare Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017559","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11102-025-01605-1","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T15:09:54Z","timestamp":1766329794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Controlling cortisol excess and comorbidities in Cushing\u2019s syndrome with osilodrostat"],"prefix":"10.1007","volume":"29","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Newell-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica R.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M.K.","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"issue":"6","key":"1605_CR1","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11102-022-01280-6","volume":"25","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Biller BMK, Bertherat J, Young J, Hatipoglu B, Arnaldi G et al (2022) Long-term efficacy and safety of osilodrostat in Cushing\u2019s disease: final results from a phase II study with an optional extension phase (LINC 2). Pituitary 25(6):959\u2013970","journal-title":"Pituitary"},{"issue":"9","key":"1605_CR2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A et al (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8(9):748\u2013761","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1605_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-22-0317","volume":"187","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Newell-Price J, Pivonello R, Shimatsu A, Auchus RJ, Scaroni C et al (2022) Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension. Eur J Endocrinol 187(4):531\u2013541","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1605_CR4","doi-asserted-by":"publisher","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","volume":"107","author":"M Gadelha","year":"2022","unstructured":"Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A et al (2022) Randomized trial of osilodrostat for the treatment of Cushing disease. J Clin Endocrinol Metab 107(7):e2882\u2013e2895","journal-title":"J Clin Endocrinol Metab"},{"key":"1605_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1236465","volume":"14","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Snyder PJ, Witek P, Bex M, Belaya Z, Turcu AF et al (2023) Long-term efficacy and safety of osilodrostat in patients with Cushing\u2019s disease: results from the LINC 4 study extension. Front Endocrinol (Lausanne) 14:1236465","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"1605_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1507\/endocrj.EJ19-0617","volume":"67","author":"T Tanaka","year":"2020","unstructured":"Tanaka T, Satoh F, Ujihara M, Midorikawa S, Kaneko T, Takeda T et al (2020) A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous Cushing\u2019s syndrome other than Cushing\u2019s disease. Endocr J 67(8):841\u2013852","journal-title":"Endocr J"},{"issue":"5","key":"1605_CR7","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf046","volume":"9","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Auchus RJ, Huang W, Spencer-Segal JL, Yuen KCJ, Dacus KC et al (2025) Osilodrostat treatment of Cushing syndrome in real-world clinical practice: findings from the ILLUSTRATE study. J Endocr Soc 9(5):bvaf046","journal-title":"J Endocr Soc"},{"issue":"1","key":"1605_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-024-01471-3","volume":"28","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Pivonello R, Newell-Price J, Gadelha MR, Biller BMK, Auchus RJ et al (2025) Osilodrostat improves blood pressure and glycemic control in patients with Cushing\u2019s disease: a pooled analysis of LINC 3 and LINC 4 studies. Pituitary 28(1):22","journal-title":"Pituitary"},{"issue":"5","key":"1605_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-017-0860-9","volume":"17","author":"G Mazziotti","year":"2017","unstructured":"Mazziotti G, Formenti AM, Frara S, Maffezzoni F, Doga M, Giustina A (2017) Diabetes in Cushing disease. Curr Diab Rep 17(5):32","journal-title":"Curr Diab Rep"},{"issue":"11","key":"1605_CR10","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1097\/HJH.0000000000003252","volume":"40","author":"F Fallo","year":"2022","unstructured":"Fallo F, Di Dalmazi G, Beuschlein F, Biermasz NR, Castinetti F, Elenkova A et al (2022) Diagnosis and management of hypertension in patients with Cushing\u2019s syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 40(11):2085\u20132101","journal-title":"J Hypertens"},{"issue":"5","key":"1605_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s11102-022-01252-w","volume":"25","author":"S Frara","year":"2022","unstructured":"Frara S, di Filippo L, Doga M, Loli P, Casanueva FF, Giustina A (2022) Novel approaches to bone comorbidity in Cushing\u2019s disease: an update. Pituitary 25(5):754\u2013759","journal-title":"Pituitary"},{"issue":"10418","key":"1605_CR12","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","volume":"402","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Gatto F, Wildemberg LE, Fleseriu M (2023) Cushing\u2019s syndrome. Lancet 402(10418):2237\u20132252","journal-title":"Lancet"},{"issue":"3","key":"1605_CR13","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf008","volume":"9","author":"G Voltan","year":"2025","unstructured":"Voltan G, Mazzeo P, Cannito M, Pinelli S, Barbot M, Scaroni C et al (2025) Relationship among fragility fractures and the overall cardiovascular burden in endogenous Cushing syndrome. J Endocr Soc 9(3):bvaf008","journal-title":"J Endocr Soc"},{"issue":"2","key":"1605_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/ejendo\/lvae098","volume":"191","author":"Y Rudman","year":"2024","unstructured":"Rudman Y, Fleseriu M, Dery L, Masri-Iraqi H, Sasson L, Shochat T et al (2024) Endogenous Cushing\u2019s syndrome and cancer risk. Eur J Endocrinol 191(2):223\u2013231","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1605_CR15","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1210\/clinem\/dgad453","volume":"109","author":"S Puglisi","year":"2023","unstructured":"Puglisi S, Perini AME, Botto C, Oliva F, Terzolo M (2023) Long-term consequences of Cushing syndrome: a systematic literature review. J Clin Endocrinol Metab 109(3):e901\u2013e919","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1605_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/ejendo\/lvaf059","volume":"192","author":"A Akirov","year":"2025","unstructured":"Akirov A, Fleseriu M, Masri-Iraqi H, Shochat T, Kushnir S, Shimon I et al (2025) Mortality in Cushing\u2019s syndrome: declining over 2 decades but remaining higher than the general population. Eur J Endocrinol 192(4):445\u2013455","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1605_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1605_CR18","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J, Savage MO et al (2015) Treatment of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807\u20132831","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1605_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-024-01485-x","volume":"28","author":"A Giustina","year":"2025","unstructured":"Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P et al (2025) Medical management pathways for Cushing\u2019s disease in pituitary tumors centers of excellence (PTCOEs). Pituitary 28(1):23","journal-title":"Pituitary"},{"issue":"5","key":"1605_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/ejendo\/lvaf207","volume":"193","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Pivonello R, Lacroix A, Biller BMK, Feelders R, Gadelha M et al (2025) Osilodrostat dose impact on efficacy\/safety in Cushing\u2019s disease: large, pooled analysis of LINC 2, 3 and 4. Eur J Endocrinol 193(5):606\u2013617","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1605_CR21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1507\/endocrj.EJ24-0153","volume":"71","author":"A Shimatsu","year":"2024","unstructured":"Shimatsu A, Biller BMK, Fleseriu M, Pivonello R, Lee EJ, Lee-lawattana R et al (2024) Osilodrostat treatment in patients with Cushing\u2019s disease of Asian or non-Asian origin: a pooled analysis of two phase III randomized trials (LINC 3 and LINC 4). Endocr J 71(12):1103\u20131123","journal-title":"Endocr J"},{"issue":"6","key":"1605_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11102-022-01268-2","volume":"25","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Biller BMK (2022) Treatment of Cushing\u2019s syndrome with osilodrostat: practical applications of recent studies with case examples. Pituitary 25(6):795\u2013809","journal-title":"Pituitary"},{"issue":"3","key":"1605_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11102-022-01218-y","volume":"25","author":"X He","year":"2022","unstructured":"He X, Findling JW, Auchus RJ (2022) Glucocorticoid withdrawal syndrome following treatment of endogenous Cushing syndrome. Pituitary 25(3):393\u2013403","journal-title":"Pituitary"},{"issue":"7","key":"1605_CR24","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1210\/clinem\/dgae250","volume":"109","author":"F Beuschlein","year":"2024","unstructured":"Beuschlein F, Else T, Bancos I, Hahner S, Hamidi O, van Hulsteijn L et al (2024) European Society of Endocrinology and Endocrine Society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. J Clin Endocrinol Metab 109(7):1657\u20131683","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1605_CR25","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R et al (2016) Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101(11):3888\u20133921","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1605_CR26","doi-asserted-by":"publisher","first-page":"K29","DOI":"10.1093\/ejendo\/lvad060","volume":"188","author":"J Poirier","year":"2023","unstructured":"Poirier J, Bonnet-Serrano F, Thomeret L, Bouys L, Bertherat J (2023) Prolonged adrenocortical blockade following discontinuation of osilodrostat. Eur J Endocrinol 188(6):K29\u2013K32","journal-title":"Eur J Endocrinol"},{"key":"1605_CR27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf552","author":"EV Varlamov","year":"2025","unstructured":"Varlamov EV, Park BJ, Fleseriu M (2025) Osilodrostat-associated adrenal gland shrinkage: a case series of patients with ACTH-dependent Cushing\u2019s syndrome. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaf552","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1605_CR28","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae201","volume":"9","author":"J Newell-Price","year":"2024","unstructured":"Newell-Price J, Fleseriu M, Pivonello R, Feelders RA, Gadelha MR, Lacroix A et al (2024) Improved clinical outcomes during long-term osilodrostat treatment of Cushing disease with normalization of late-night salivary cortisol and urinary free cortisol. J Endocr Soc 9(1):bvae201","journal-title":"J Endocr Soc"},{"issue":"12","key":"1605_CR29","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1210\/clinem\/dgaf206","volume":"110","author":"D Ferrari","year":"2025","unstructured":"Ferrari D, Bonaventura I, Simeoli C, Tomaselli A, Vincenzi L, De Alcubierre D et al (2025) Chronotherapy with once-daily osilodrostat improves cortisol rhythm, quality of life, and sleep in Cushing\u2019s syndrome. J Clin Endocrinol Metab 110(12):3525\u20133537","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1605_CR30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1210\/endrev\/bnae016","volume":"45","author":"SA Clarke","year":"2024","unstructured":"Clarke SA, Eng PC, Comninos AN, Lazarus K, Choudhury S, Tsang C et al (2024) Current challenges and future directions in the assessment of glucocorticoid status. Endocr Rev 45(6):795\u2013817","journal-title":"Endocr Rev"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01605-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:38:04Z","timestamp":1773682684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01605-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01605-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,21]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MF reports grants to her university from Crinetics and Sparrow and occasional scientific consulting fees from Crinetics, Recordati Rare Diseases, Sparrow, and Xeris Pharmaceuticals; she served as a member of the LINC 3 steering committee and is a member of the editorial board of Pituitary. JN-P reports research grants and consultancy payments to his university from Crinetics, Diurnal, and Sparrow. MRG has received speaker fees from Recordati Rare Diseases and attended advisory boards for Crinetics Pharmaceuticals and Recordati Rare Diseases; she is a research investigator for Crinetics Pharmaceuticals and Recordati Rare Diseases and is a member of the editorial board of Pituitary. BMKB reports serving as the principal investigator of a study with a research grant to her hospital from Crinetics and occasional consulting honoraria from Crinetics, H Lundbeck A\/S, Recordati Rare Diseases, and Xeris Pharmaceuticals; she served on the LINC 3 steering committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}